bNAbs and Anti-PD-1 in HIV

Inclusion Criteria: * Ability and willingness to provide informed consent * HBV sAg or HBV DNA as well as HCV Ag or HCV RNA negative or anti-core antibody negative * Current CD4 count \>500 cells/μL (at screening) * Plasma HIV-1 RNA \<50 copies/mL by standard assays for at least 15 months (a single measurement \>50 but \<500 copies/mL during this time period is allowable) * On integrase inhibitor (INSTI) or boosted protease inhibitor (PI) based regimen at time of randomization, if previously on non-nucleoside reverse transcriptase inhibitor (NNRTI) has switched at least 4 weeks prior to randomization * Females of childbearing potential (i.e., participants who have not been postmenopausal for at least 24 consecutive months, who have had menses within the preceding 24 months, or who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy), negative serum or urine pregnancy test monthly * Pregnancy prevention (heterosexual contact(s)): o Females must agree to use highly eWective contraceptive methods: Hormonal contraception, intrauterine device, or intrauterine hormone-releasing system from at least 2 weeks before the bNAb infusion and for entire trial period of 60 weeks and 15 months following the bNAb infusion * Transmission prevention * Participants must agree to use barrier prevention during ART interruption and until plasma HIV-1 RNA levels are resuppressed again following ART re-start * Partners of study participants should be willing to receive counselling on the need for PrEP according to national recommendations Exclusion Criteria: * Current, or history of: * Clinically significant cardiovascular disease (e.g., cardiac insuWiciency, coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long QT syndrome, family history of sudden death) * Malignancy, excluding non-melanoma skin cancers * Solid organ transplant * Autoimmune or antibody-mediated diseases (including not limited to type 1 diabetes mellitus, inflammatory bowel diseases, scleroderma, severe psoriasis, myocarditis, uveitis, pneumonitis, systemic lupus erythematosus, rheumatoid arthritis, optic neuritis, myasthenia gravis, adrenal insuWiciency, hypothyroidism and/or hyperthyroidism, autoimmune thyroiditis, sarcoidosis, and vitiligo) * Known hypersensitivity to the components of 3BNC117-LS, 10-1074-LS or nivolumab or their analogues * HIV-1 reservoir predicted resistant to neutralization by 10-1074 using genotypic analysis (as defined in section 11.3.2.9) * Known HIV-1 subtype CRF01-AE due to resistance to 10-1074-LS * Receipt of strong immunosuppressive or systemic chemotherapeutic agents within 28 days prior to screening * Laboratory abnormalities in the parameters listed below: * Estimated glomerular filtration rate (eGFR) \<60 mL/min * AST or ALT \>x1.25 upper limit of normal (ULN) * Positive Quantiferon test * TPO antibodies \>35 IU/mL * Partial thromboplastin time \>1.25 ULN * Pregnancy or lactation * Any vaccination 2 weeks prior to baseline * Any significant acute infection (e.g. influenza, COVID-19) or any other clinically significant illness 2 weeks prior to screening * Have received a long-acting ART regimen within the last 12 months (e.g. cabotegravir or lenacaprivir containing regimen) * Known resistance to \>2 classes of ART * Participation in other interventional trial * Any other conditions, which in the opinion of the investigator would make the participant unsuitable for inclusion, or could interfere with the participants participating in or completion of the study